Researchers at Scripps Research have developed a nanodisc-based platform that lets scientists study viral surface proteins in a membrane-like environment mimicking real viruses. Published in Nature Communications, the study revealed previously invisible interactions between antibodies and viruses like HIV and Ebola that traditional methods missed entirely.
The platform embeds viral glycoproteins into tiny lipid particles that preserve their natural structure and behavior. What previously took a month or longer to prepare can now be done in about a week, dramatically accelerating vaccine candidate screening. Lead researcher William Schief said the technology "lets us study these proteins in a setting that better reflects their natural environment, which is critical if we want to understand how protective antibodies recognize a virus."
Beyond HIV and Ebola, the platform is applicable to other membrane-bound viruses including influenza and SARS-CoV-2, opening new avenues for faster and more effective vaccine design.